All patients were HER-2 negative and were stratified by Combined Prognostic Score (CPS evaluates the number of PD⁠-⁠L1–staining cells (tumor cells, lymphocytes, macrophages) relative to all viable tumor cells) of which 60% (chemo plus nivo) and 61% (chemo) of patients had CPS ≥ 5. The gene discussed is ERBB2; the disease is neoplasm.